Comparison of protective effects of hesperetin and pectolinarigenin on high-fat diet-induced hyperlipidemia and hepatic steatosis in Golden Syrian hamsters

Abstract

A comparative study was conducted to determine whether hesperetin and pectolinarigenin could lower total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL) in a high-fat diet (HFD)-induced high lipid model in Golden Syrian hamsters. 48 Golden Syrian hamsters (8 weeks old) were fed with a HFD for 15 days. HFD induced significant increases in plasma TC, TG, LDL, and HDL. Then, these high lipid hamsters were divided into four groups and were administered with 0.5% sodium carboxymethyl cellulose (CMC-Na), hesperetin (100 mg/kg/day), pectolinarigenin (100 mg/kg/day) or atorvastatin (1.0 mg/kg/day), for 7 weeks. It was found that pectolinarigenin treatment resulted in significant reductions in body weight, adiposity index, serum levels of TC, TG and hepatic TC, TG and free fatty acid compared to those in control hamsters with hyperlipidemia (P<0.05). However, hesperetin treatment only caused reductions in plasma TC and hepatic TG levels. Besides, the hamsters treated with pectolinarigenin showed a relatively normal hepatic architecture compared to the hepatic steatosis shown in the control group. Moreover, the expressions of fatty-acid synthase (Fasn) and solute carrier family 27 member 1 (Slc27a1) involved in lipid biosynthesis, were suppressed in the pectolinarigenin-treated groups, and the expression of carnitine palmitoyltransferase 1A (Cpt1a) involved in fatty acid oxidation was increased in the pectolinarigenin-treated group. Taken together, these results suggest pectolinarigenin exerts stronger protective effects against hyperlipidemia and hepatic steatosis than hesperetin, which may involve the inhibition of lipid uptake and biosynthesis.

The in vivo study on antioxidant activity of wendan decoction in treating hyperlipidemia: a pharmacokinetic-pharmacodynamic (PK-PD) model

“…Hesperidin can reduce altered redox homeostasis in experimental hyperlipidemia rat models ( Kumar et al, 2020 ). Compared with the control group, the body weight, obesity index, serum TC, TG, liver TC, TG and free fatty acid levels of hyperlipidemia hamsters treated with hesperetin were significantly decreased ( Shi et al, 2023 ). Available evidence from randomized controlled trials suggests that quercetin supplementation does not have any clinically relevant effect on plasma lipids, except for a significant reduction in triglycerides at doses above 50 mg/day ( Sahebkar, 2017 ).…”

Inhibitory interaction of flavonoids with organic cation transporter 2 and their structure–activity relationships for predicting nephroprotective effects

“…We found that 10 out of 96 flavonoids significantly inhibited OCT2. Among them, pectolinarigenin, luteolin, echinatin, chrysin, flavone, 6‐hydroxyflavone, and pinocembrin are the main active ingredients in some frequently used TCM (Cheriet et al, 2020; Fu et al, 2013; Imran et al, 2019; Naz et al, 2019; Rasul et al, 2013; Shi et al, 2022). Pectolinarigenin is mainly found in Cirsium japonicum , luteolin is the main active ingredient in Lonicera japonica , echinatin is abundant in Glycyrrhiza inflata , chrysin and pinocembrin are plentiful in Propolis, flavone is found in Ginkgo biloba L, and 6‐hydroxyflavone is extracted from Barleria prionitis Linn.…”

“…The administration dose of flavonoids was adopted from reports in the literature. The mice were pretreated by oral gavage with a single dose of 100 mg/kg for chrysin (Xu et al, 2019), biochanin A (Liu et al, 2016), 6‐methylflavone, 6‐hydroxyflavone (Din et al, 2020), and pectolinarigenin (Shi et al, 2022), whereas 200 mg/kg for luteolin (Li et al, 2022). Wedelolactone (100 mg/kg) was employed as the positive control (Wang et al, 2021).…”

Inhibitory effect of trans-tiliroside on very low-density lipoprotein secretion in HepG2 cells and mouse liver

“…In this study, we investigated the effects of compound 1 on the secretion of CHO, TG, and apoB-100 in HepG2 cells and mice. We also evaluated the inhibitory effects of nobiletin ( 2 ) [ 25 – 27 ], hesperidin ( 3 ) [ 28 – 30 ], and hesperetin ( 4 ) [ 31 , 32 ] (Fig. 1 ), the citrus-derived components with reported anti-hyperlipidemic effects, on CHO secretion in HepG2 cells and compared their mode of action with that of compound 1 .…”